Evolus, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual report, not a standalone fourth-quarter filing; it reports fourth-quarter 2020 net revenue of $20.6 million. Evolus is an aesthetics-focused company whose revenue came entirely from Jeuveau, its botulinum toxin product for glabellar lines.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Total net revenue | $56.5 million | $34.9 million |
| Product cost of sales | $18.3 million | $8.0 million |
| Gross margin | 67.6% | 77.1% |
| Operating loss | $153.1 million | $98.9 million |
| Net loss | $163.0 million | $90.0 million |
| Cash used in operating activities | $57.9 million | $93.4 million |
- Year-end cash and cash equivalents were $102.6 million, with $5.0 million in short-term investments. Current assets were $127.6 million against current liabilities of $180.2 million.
- At year-end, debt included $74.4 million of Oxford term loan and $40.5 million on the Daewoong convertible note. Evolus also had a $20.0 million founder promissory note due in November 2021 and a $41.5 million contingent royalty obligation to founders.
- On January 4, 2021, Evolus paid $76.4 million to repay Oxford in full; Oxford waived approximately $4.3 million of fees. The Daewoong note was converted in March 2021 into 3,136,869 shares.
Changes versus 2019
- Revenue rose $21.6 million, primarily on higher U.S. sales volume, partly offset by a lower net average selling price.
- Gross margin declined from 77.1% to 67.6%, reflecting marketing programs, higher-cost inventory after launch-priced inventory was depleted, and royalties that began accruing on December 16, 2020.
- SG&A fell to $98.2 million from $113.6 million, and R&D fell to $1.7 million from $4.0 million, largely due to spending reductions and completed U.S. clinical work. Restructuring costs were $3.0 million.
- The $163.0 million net loss included $83.4 million of litigation settlement expense. The settlement was agreed in February 2021 but recorded in 2020: $35.0 million in cash obligations and $48.4 million settled through shares.
- Operating cash use improved year over year, but cash fell $7.3 million during 2020. Financing included $40.0 million of proceeds from the Daewoong note.
Outlook, commentary and key risks
- Going concern: Management said available resources were insufficient to meet obligations and fund operations for at least 12 months, and the auditor’s report highlighted substantial doubt about continued operations without additional capital. Evolus reported recurring losses, negative operating cash flow and an accumulated deficit of $376.1 million.
- Litigation settlement: The February 2021 Medytox/Allergan agreements provided licenses and for dismissal of litigation and rescission of ITC remedial orders. Terms include $35.0 million in cash payments, share issuance of 6,762,652 shares, and royalties. The filing says royalties are expected to materially reduce gross margin through September 2022 and have a smaller negative impact through September 2032. Daewoong agreed to pay Evolus $25.5 million, cover certain legal fees, cancel up to $10.5 million of milestones, and reimburse certain U.S. royalty amounts.
- Commercial outlook: The company planned a European launch in early 2022. It provided no specific revenue or earnings guidance in the supplied filing text.
- COVID-19: Customer closures and deferred elective procedures hurt sales from mid-March 2020; sales began increasing in June as restrictions eased. Evolus cut more than 100 employees, reduced executive and board compensation temporarily, and delayed the European launch. Management said the pandemic’s future effects remained uncertain.
- Business risks: Evolus depends on a single product and a single manufacturer, Daewoong; faces established competitors and consumer-discretionary demand risk; needs further financing; and could face dilution or operational constraints if it raises capital. Securities class-action and derivative cases remained unresolved, with no loss estimate accrued.
Investor verification points
- Confirm the company’s post-year-end liquidity after the Oxford payoff, settlement payments, the Daewoong payment and ongoing operating cash needs; additional financing was considered necessary.
- Review the settlement’s cash-payment schedule, per-vial and net-sales royalty terms, Daewoong reimbursement provisions, and resulting gross-margin effect.
- Assess share dilution from the 6,762,652 Medytox shares and 3,136,869 Daewoong conversion shares, alongside any potential future financing.
- Track Jeuveau sales, pricing, customer adoption and the impact of COVID-19 and competition; the product is the company’s sole source of revenue.
- Monitor Daewoong supply and license conditions, unresolved shareholder litigation, and progress toward the planned European launch.